As a long-acting antibody platform technology, hyFc technology was developed to lead to long-acting drugs. It combines the advantages of bio-derived substances IgG4 and IgD, which are not recognized as immunogens in vivo.
IgD has high hinge flexibility, minimizing protein-to-protein interaction to increase drug efficacy, and lowering cytotoxicity problems through ADCC and CDC. By binding with FcRn, IgG4 is recycled (regeneration) in vivo, enabling it to have long-acting (persistence) through this.
Antibody fusion protein has long-acting in vivo through cellular blood circulation process.